



Celldex Therapeutics, Inc.  
Investor Relations Department  
119 Fourth Avenue  
Needham, MA 02494-2725  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

<b>NASDAQ: CLDX</b> <sup>1</sup>	
Last Trade:	0.59
Trade Time:	4:00 PM ET Jun 19, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.58 - 3.26
Volume	127
Market Cap. (\$M)	84.457
Shares Out (M)	143.390

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 2, 2018*

[Celldex Presents Promising Data from Phase 1/2 Study of Varilumab and Opdivo® at 2018 ASCO Annual Meeting](#)

*Jun 1, 2018*

[Celldex Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference](#)

*May 16, 2018*

[Celldex Announces Presentations at the 2018 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)

*May 10, 2018*

[Celldex Provides Corporate Update and Reports First Quarter 2018 Results](#)

*Apr 20, 2018*

[Data from Multiple Celldex Programs Presented at American Association for Cancer Research \(AACR\) Annual Meeting 2018](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [First Quarter Financial Results](#)

*Mar 7, 2018*

[Annual Report \(10-K\)](#)

*Apr 30, 2018*

[Definitive Proxy Statement](#)

*May 10, 2018*

[Quarterly Report \(10-Q\)](#)

*Nov 7, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 8, 2017*

[Quarterly Report \(10-Q\)](#)